318 related articles for article (PubMed ID: 35453626)
1. New Approaches to Diabetic Nephropathy from Bed to Bench.
Tsai JL; Chen CH; Wu MJ; Tsai SF
Biomedicines; 2022 Apr; 10(4):. PubMed ID: 35453626
[TBL] [Abstract][Full Text] [Related]
2. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study.
Iwai T; Miyazaki M; Yamada G; Nakayama M; Yamamoto T; Satoh M; Sato H; Ito S
Clin Exp Nephrol; 2018 Apr; 22(2):328-336. PubMed ID: 28752289
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Management of Diabetic Nephropathy in Western Countries.
Satirapoj B; Adler SG
Kidney Dis (Basel); 2015 May; 1(1):61-70. PubMed ID: 27536666
[TBL] [Abstract][Full Text] [Related]
7. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
8. Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets.
Zoja C; Xinaris C; Macconi D
Front Pharmacol; 2020; 11():586892. PubMed ID: 33519447
[TBL] [Abstract][Full Text] [Related]
9. Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy.
Pappa M; Dounousi E; Duni A; Katopodis K
Int Urol Nephrol; 2015 Aug; 47(8):1365-72. PubMed ID: 26017902
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
Packer M
Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
[TBL] [Abstract][Full Text] [Related]
11. Up-Date on Diabetic Nephropathy.
Pelle MC; Provenzano M; Busutti M; Porcu CV; Zaffina I; Stanga L; Arturi F
Life (Basel); 2022 Aug; 12(8):. PubMed ID: 36013381
[TBL] [Abstract][Full Text] [Related]
12. A Narrative Review of New Treatment Options for Diabetic Nephropathy.
Pillai A; Fulmali D
Cureus; 2023 Jan; 15(1):e33235. PubMed ID: 36733548
[TBL] [Abstract][Full Text] [Related]
13. Effect of extract of Pueraria tuberosa on expression of hypoxia inducible factor-1α and vascular endothelial growth factor in kidney of diabetic rats.
Shukla R; Pandey N; Banerjee S; Tripathi YB
Biomed Pharmacother; 2017 Sep; 93():276-285. PubMed ID: 28648975
[TBL] [Abstract][Full Text] [Related]
14. An Updated Review on Diabetic Nephropathy: Potential Mechanisms, Biomarkers, Therapeutic Targets and Interventional Therapies.
Nadendla RR; K K; Aziz N; Pyne C; Panigrahy UP; Wal P; Kulkarni MH; Rasheed A
Curr Diabetes Rev; 2024 Jun; ():. PubMed ID: 38919001
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
Cherney DZ; Perkins BA
Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
[TBL] [Abstract][Full Text] [Related]
17. Histological changes of kidney in diabetic nephropathy.
Pourghasem M; Shafi H; Babazadeh Z
Caspian J Intern Med; 2015; 6(3):120-7. PubMed ID: 26644877
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Škrtić M; Cherney DZ
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
[TBL] [Abstract][Full Text] [Related]
19. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
